AlphaMedix not checked

Orano Med LLC · Pb212-octreotide analog

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
None yet
 
Trials
1 active
2 in total
Targets
 

What this is

How it works
How it works isn't classified yet
How it’s given
“212Pb-DOTAMTATE is a radiolabeled derivative of octreotide targeting somatostatin positive neuroendocrine tumors”In the company’s words, NCT05153772 on ClinicalTrials.gov
Tested for
Neuroendocrine Tumors
Main trialPhase 2
“Multicenter Phase 2 study of 212Pb-DOTAMTATE enrolling adult subjects with positive somatostatin positive neuroendocrine tumors with either no prior history of peptide receptor radionuclide therapy (PRRT naive) or prior history of peptide receptor radionuclide therapy (Previous PRRT)”In the company’s words, NCT05153772 on ClinicalTrials.gov
Other names
Pb212-octreotide analog

Other drugs for Neuroendocrine Tumors

All 245 drugs for Neuroendocrine Tumors

Coming up0

No dates coming up.

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials2

TrialPhaseCompletesWhat it tests
Phase 2Active, not recruiting 14 Apr 2025 Targeted Alpha-emitter Therapy of PRRT Naïve and Previous PRRT Neuroendocrine Tumor Patients
Phase 1Terminated 6 Apr 2023 Phase 1 Study of AlphaMedix™ in Adult Subjects With SSTR (+) NET
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow AlphaMedix

Following is part of Solo: you see every change to AlphaMedix the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in